Journal article
Fingolimod-associated macular edema controlled with nepafenac non-steroidal anti-inflammatory opthalmologic applications
Clinical and molecular allergy CMA, Vol.18(1), pp.3-4
03/12/2020
DOI: 10.1186/s12948-020-00119-4
PMCID: PMC7066779
PMID: 32190009
Abstract
Background
Fingolimod, an immunomodulatory agent, is used for the treatment of relapsing–remitting multiple sclerosis (RRMS). Fingolimod-associated macular edema (FAME) is a known complication with an incidence of 0.4%. The current recommendation for treatment of FAME is cessation of fingolimod. There are few case reports with management of FAME with steroid eye drops.
Case presentation
A 38-year-old Caucasian female patient with history of relapsing–remitting multiple sclerosis (RRMS) and treated with fingolimod developed Fingolimod-associated macular edema (FAME). Nevertheless, FAME was successfully treated with nonsteroidal anti-inflammatory eye drops without discontinuation of fingolimod.
Conclusion
FAME may be managed with non-steroidal eye drops without discontinuation of fingolimod in appropriate patient monitored with close follow up.
Details
- Title: Subtitle
- Fingolimod-associated macular edema controlled with nepafenac non-steroidal anti-inflammatory opthalmologic applications
- Creators
- Rachel Husmann - University of MinnesotaJohn B. Davies - ViteroRetinal SurgeryMalik Ghannam - University of MinnesotaBrent Berry - University of MinnesotaPraful Kelkar - Minneapolis Clinic of Neurology, 4225 Golden Valley Road, Golden Valley, MN 55422 USA
- Resource Type
- Journal article
- Publication Details
- Clinical and molecular allergy CMA, Vol.18(1), pp.3-4
- Publisher
- BioMed Central
- DOI
- 10.1186/s12948-020-00119-4
- PMID
- 32190009
- PMCID
- PMC7066779
- ISSN
- 1476-7961
- eISSN
- 1476-7961
- Language
- English
- Date published
- 03/12/2020
- Academic Unit
- Neurology
- Record Identifier
- 9984585426002771
Metrics
3 Record Views